80 related articles for article (PubMed ID: 23754601)
1. Loss of heterozygosity at 13q13 and 14q32 predicts BRCA2 inactivation in luminal breast carcinomas.
Pécuchet N; Popova T; Manié E; Lucchesi C; Battistella A; Vincent-Salomon A; Caux-Moncoutier V; Bollet M; Sigal-Zafrani B; Sastre-Garau X; Stoppa-Lyonnet D; Stern MH
Int J Cancer; 2013 Dec; 133(12):2834-42. PubMed ID: 23754601
[TBL] [Abstract][Full Text] [Related]
2. Prediction of BRCA2-association in hereditary breast carcinomas using array-CGH.
Joosse SA; Brandwijk KI; Devilee P; Wesseling J; Hogervorst FB; Verhoef S; Nederlof PM
Breast Cancer Res Treat; 2012 Apr; 132(2):379-89. PubMed ID: 20614180
[TBL] [Abstract][Full Text] [Related]
3. BRCA1 and BRCA2 mutation status and tumor characteristics in male breast cancer: a population-based study in Italy.
Ottini L; Masala G; D'Amico C; Mancini B; Saieva C; Aceto G; Gestri D; Vezzosi V; Falchetti M; De Marco M; Paglierani M; Cama A; Bianchi S; Mariani-Costantini R; Palli D
Cancer Res; 2003 Jan; 63(2):342-7. PubMed ID: 12543786
[TBL] [Abstract][Full Text] [Related]
4. Chromosome 5 imbalance mapping in breast tumors from BRCA1 and BRCA2 mutation carriers and sporadic breast tumors.
Johannsdottir HK; Jonsson G; Johannesdottir G; Agnarsson BA; Eerola H; Arason A; Heikkila P; Egilsson V; Olsson H; Johannsson OT; Nevanlinna H; Borg A; Barkardottir RB
Int J Cancer; 2006 Sep; 119(5):1052-60. PubMed ID: 16570289
[TBL] [Abstract][Full Text] [Related]
5. Reduced Fhit expression in sporadic and BRCA2-linked breast carcinomas.
Ingvarsson S; Agnarsson BA; Sigbjornsdottir BI; Kononen J; Kallioniemi OP; Barkardottir RB; Kovatich AJ; Schwarting R; Hauck WW; Huebner K; McCue PA
Cancer Res; 1999 Jun; 59(11):2682-9. PubMed ID: 10363992
[TBL] [Abstract][Full Text] [Related]
6. Landscape of somatic allelic imbalances and copy number alterations in HER2-amplified breast cancer.
Staaf J; Jönsson G; Ringnér M; Baldetorp B; Borg A
Breast Cancer Res; 2011; 13(6):R129. PubMed ID: 22169037
[TBL] [Abstract][Full Text] [Related]
7. High incidence and frequency of LOH are associated with aggressive features of high-grade HER2 and triple-negative breast cancers.
Tokunaga E; Okada S; Yamashita N; Akiyoshi S; Kitao H; Morita M; Kakeji Y; Maehara Y
Breast Cancer; 2012 Apr; 19(2):161-9. PubMed ID: 21063923
[TBL] [Abstract][Full Text] [Related]
8. Deletions on chromosome 4 in sporadic and BRCA mutated tumors and association with pathological variables.
Johannsdottir HK; Johannesdottir G; Agnarsson BA; Eerola H; Arason A; Johannsson OT; Heikkilä P; Egilsson V; Olsson H; Borg A; Nevanlinna H; Barkardottir RB
Anticancer Res; 2004; 24(5A):2681-7. PubMed ID: 15521105
[TBL] [Abstract][Full Text] [Related]
9. Genomic and phenotypic analysis of BRCA2 mutated breast cancers reveals co-occurring changes linked to progression.
Stefansson OA; Jonasson JG; Olafsdottir K; Bjarnason H; Th Johannsson O; Bodvarsdottir SK; Valgeirsdottir S; Eyfjord JE
Breast Cancer Res; 2011 Sep; 13(5):R95. PubMed ID: 21958427
[TBL] [Abstract][Full Text] [Related]
10. Loss of heterozygosity at BRCA2 in a ductal carcinoma in situ and three invasive breast carcinomas in a family with a germline BRCA2 mutation.
Thomassen M; Kruse TA; Olsen KE; Borg A; Gerdes AM
Breast Cancer Res Treat; 2004 Oct; 87(3):273-6. PubMed ID: 15528970
[TBL] [Abstract][Full Text] [Related]
11. High incidence of loss of heterozygosity at chromosome 17p13 in breast tumours from BRCA2 mutation carriers.
Eiriksdottir G; Barkardottir RB; Agnarsson BA; Johannesdottir G; Olafsdottir K; Egilsson V; Ingvarsson S
Oncogene; 1998 Jan; 16(1):21-6. PubMed ID: 9467939
[TBL] [Abstract][Full Text] [Related]
12. Phenotypic analysis of familial breast cancer: comparison of BRCAx tumors with BRCA1-, BRCA2-carriers and non-familial breast cancer.
Aloraifi F; Alshehhi M; McDevitt T; Cody N; Meany M; O'Doherty A; Quinn CM; Green AJ; Bracken A; Geraghty JG
Eur J Surg Oncol; 2015 May; 41(5):641-6. PubMed ID: 25736863
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical characteristics defined by tissue microarray of hereditary breast cancer not attributable to BRCA1 or BRCA2 mutations: differences from breast carcinomas arising in BRCA1 and BRCA2 mutation carriers.
Palacios J; Honrado E; Osorio A; Cazorla A; Sarrió D; Barroso A; Rodríguez S; Cigudosa JC; Diez O; Alonso C; Lerma E; Sánchez L; Rivas C; Benítez J
Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3606-14. PubMed ID: 14506147
[TBL] [Abstract][Full Text] [Related]
14. Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Breast Cancer Linkage Consortium.
Lancet; 1997 May; 349(9064):1505-10. PubMed ID: 9167459
[TBL] [Abstract][Full Text] [Related]
15. Deletion of chromosomes 13q and 14q is a common feature of tumors with BRCA2 mutations.
Rouault A; Banneau G; Macgrogan G; Jones N; Elarouci N; Barouk-Simonet E; Venat L; Coupier I; Letouzé E; de Reyniès A; Bonnet F; Iggo R; Sévenet N; Longy M
PLoS One; 2012; 7(12):e52079. PubMed ID: 23284877
[TBL] [Abstract][Full Text] [Related]
16. Consortium study on 1280 breast carcinomas: allelic loss on chromosome 17 targets subregions associated with family history and clinical parameters.
Phelan CM; Borg A; Cuny M; Crichton DN; Baldersson T; Andersen TI; Caligo MA; Lidereau R; Lindblom A; Seitz S; Kelsell D; Hamann U; Rio P; Thorlacius S; Papp J; Olah E; Ponder B; Bignon YJ; Scherneck S; Barkardottir R; Borresen-Dale AL; Eyfjörd J; Theillet C; Thompson AM; Larsson C
Cancer Res; 1998 Mar; 58(5):1004-12. PubMed ID: 9500463
[TBL] [Abstract][Full Text] [Related]
17. Loss of heterozygosity at BRCA1 locus is significantly associated with aggressiveness and poor prognosis in breast cancer.
Okada S; Tokunaga E; Kitao H; Akiyoshi S; Yamashita N; Saeki H; Oki E; Morita M; Kakeji Y; Maehara Y
Ann Surg Oncol; 2012 May; 19(5):1499-507. PubMed ID: 22179631
[TBL] [Abstract][Full Text] [Related]
18. Genomic differences between estrogen receptor (ER)-positive and ER-negative human breast carcinoma identified by single nucleotide polymorphism array comparative genome hybridization analysis.
Fang M; Toher J; Morgan M; Davison J; Tannenbaum S; Claffey K
Cancer; 2011 May; 117(10):2024-34. PubMed ID: 21523713
[TBL] [Abstract][Full Text] [Related]
19. Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCA1/2 inactivation.
Popova T; Manié E; Rieunier G; Caux-Moncoutier V; Tirapo C; Dubois T; Delattre O; Sigal-Zafrani B; Bollet M; Longy M; Houdayer C; Sastre-Garau X; Vincent-Salomon A; Stoppa-Lyonnet D; Stern MH
Cancer Res; 2012 Nov; 72(21):5454-62. PubMed ID: 22933060
[TBL] [Abstract][Full Text] [Related]
20. Loss of BRCA2 correlates with reduced long-term survival of sporadic breast cancer patients.
Hampl JA; Hampl M; Reiss G; Koch R; Saeger HD; Schackert HK
Anticancer Res; 2004; 24(1):281-90. PubMed ID: 15015609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
